1972年在卡罗林斯卡(Karolinska)研究所开始首次临床试验白细胞干扰素,当时它被用于治疗骨肉瘤。其他癌也用它来治疗并寄予了很高的期望,即认为这种新的“生物反应改变因子”将是癌症治疗的一个突破。然而药物的效果被夸大了。用第一批使用干扰素的一个人的话来说,“大量的二级研究是用被轻微污染了的干扰素三级制剂来进行的”。 The first clinical trial of leukocyte interferon began in the Karolinska Institute in 1972 when it was used to treat osteosarcoma. Other cancers have also used it to treat and place high hopes that this new “bioreaction change factor” will be a breakthrough in cancer treatment. However, the effects of drugs have been exaggerated. In the words of the first person who used interferon, “a large number of secondary studies were conducted using lightly contaminated interferon tertiary formulations.”